Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica PICNH2Ca for Late Stage Cancer PatientsReport as inadecuate




Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica PICNH2Ca for Late Stage Cancer Patients - Download this document for free, or read online. Document in PDF available to download.

The composition of Pamica PICNH2Ca2 is dsRNA polyI:C, non-biotics amino compounds and CaCl2. It is the second generation noncytotoxic product of PICKCa PIKA adjuvant which was found effective in phase II clinical trial for PICKCa rabies vaccine and phase I trial for PICKCa hepatitis B vaccine in Singapore. With their knowledge and consent, cancer patients, regardless of their tumor types or performance status ECOG above 5 or ECOG > 20, who were unresponsive to standard treatment, were treated free of charge with Pamica by injection or nasal spray. The primary results indicated that Pamica had no side effect except for a few cases of local pain in the site of injection and appeared to markedly improve cancer patients’ appetite, physical strength, quality of life and extended patients’ life for months and counting. These preliminary findings underlined promise of this potentially life-saving drug. In the hope of cooperating with the proper authorities, companies, and hospitals to benefit patients at the earliest opportunity, we share our findings in this paper.

KEYWORDS

Cancer Immunotherapy, DS RNA, TLR3, Terminal Cancer, Adjuvant, PICKCa, PIKA, Pamica

Cite this paper

Lin, H. and Liu, F. 2017 Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica PICNH2Ca for Late Stage Cancer Patients. Journal of Biosciences and Medicines, 5, 49-54. doi: 10.4236-jbm.2017.52005.





Author: Haixiang Lin*, Fang Liu

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents